Three-Biomarker Panel Accurately Predicts Steroid-Induced Osteonecrosis Progression, Suggests Study
A recent retrospective study published in the Indian Journal of Orthopaedics in September 2026 shows that a three-marker blood panel combining microRNA-132, bone morphogenetic protein-2, and nuclear factor-κB receptor activator accurately tracks disease severity and femoral head collapse in steroid-induced osteonecrosis. This combined biomarker assay enables clinicians to reliably evaluate disease progression with an impressive area under the curve of 0.906.
Steroid-associated osteonecrosis of the femoral head (SANFH) remains a debilitating orthopedic challenge characterized by progressive osteocyte ischemia and collapse, yet non-invasive molecular tools for tracking early pathology have historically lacked objective precision. Addressing this clinical gap, Feng Jiang and co-investigators evaluated the expression patterns and biological relevance of serum miR-132, BMP-2, and RANK in affected patients.
Therefore, the retrospective study evaluated serum biomarker levels in 108 patients with steroid-associated osteonecrosis of the femoral head across Association Research Circulation Osseous (ARCO) stages I–III alongside 120 healthy controls. Excluding non-steroid etiologies, researchers correlated marker concentrations with disease stage and femoral head collapse using Pearson correlation and receiver operating characteristic (ROC) curve analyses.
- Altered Serum Expression Profiles: Investigators demonstrated that patients with SANFH exhibited significantly lower serum miR-132 and BMP-2 concentrations alongside elevated RANK levels compared to healthy controls (P < 0.05).
- Association with Femoral Collapse: Researchers observed that patients in the femoral head collapsed subgroup maintained significantly lower miR-132 and BMP-2 levels and higher RANK expression than non-collapsed individuals (P < 0.05).
- Stage-Dependent Marker Shift: Analysis confirmed a progressive stepwise reduction in miR-132 and BMP-2 paired with a continuous increase in RANK across ARCO stages I, II, and III (P < 0.05).
- Disease Severity Correlation: Authors identified strong inverse correlations between ARCO staging and miR-132 or BMP-2 levels, whereas RANK displayed a direct positive correlation with stage severity (P < 0.05).
- Enhanced Diagnostic Performance: Findings established that multi-marker screening achieved an AUC of 0.906 with 82.50% sensitivity and 83.33% specificity, demonstrating superior predictive power over single biomarker assessments (Z = -1.967, -2.831, -2.891; all P < 0.05).
The results suggest that serum miR-132, BMP-2, and RANK expression levels closely mirror histological and radiological progression in SANFH. Consequently, utilizing this joint three-marker diagnostic panel (AUC 0.906, 82.50% sensitivity, 83.33% specificity) provides clinicians with a robust quantitative framework to assess disease severity and monitor femoral osteonecrosis development.
Thus, the study concludes clinicians may consider integrating circulating miR-132, BMP-2, and RANK measurements into routine orthopedic evaluations as non-invasive biological indicators to assist in tracking SANFH progression and guiding timely therapeutic decisions.
While the single-center retrospective study offers compelling diagnostic evidence, broader multi-center prospective trials involving larger patient cohorts would be beneficial to validate these molecular markers across diverse patient populations.
Reference
Jiang F, Xie X, Zhang X, Wang N, Zheng L. The Expression Levels and Clinical Significance of microRNA-132, Bone Morphogenetic Protein-2, and Nuclear Factor KB Receptor Activator in Patients with Steroid-Induced Osteonecrosis of the Femoral Head. Indian Journal of Orthopaedics. 2026; Published online September 11, 2026.
